An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.
OBJECTIVE
A phase III randomized trial that compared the combination of cetuximab and radiotherapy to radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck provided a platform for a comprehensive economic evaluation. The study was conducted to estimate the cost-effectiveness of cetuximab in combination with radiotherapy compared to radiotherapy alone, for the treatment of locally advanced head and neck cancer in patients for whom chemoradiotherapy is inappropriate or intolerable.


METHODS
Separate economic analyses were conducted for Belgium, France, Italy, Switzerland, and the United Kingdom. The economic model was based on individual patient data extracted from an international phase III trial. Country-specific costs of care from official sources were applied in each analysis. Clinical expert panels supplemented resource use estimates from the phase III trial and validated assumptions used to extrapolate costs and health outcomes beyond the follow-up of the phase III trial.


RESULTS
In the base-case analysis, the incremental cost per quality-adjusted life-year for patients receiving radiotherapy in combination with cetuximab compared to radiotherapy alone among all countries was in the range of 7538 euros to 10,836 euros. Sensitivity analysis showed the results to be robust.


CONCLUSIONS
This cost-effectiveness analysis indicated that the addition of cetuximab to high-dose radiotherapy offers a good value-for-money alternative to radiotherapy alone in the treatment of locally advanced head and neck cancer in five European countries.
Brown
Ben
B
IMS Health, London, UK.
Diamantopoulos
Alexander
A
Bernier
Jacques
J
Schöffski
Patrick
P
Hieke
Klaus
K
Mantovani
Lorenzo
L
Launois
Robert
R
Griebsch
Ingolf
I
Robinson
Paul
P
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001530:Belgium; D000068818:Cetuximab; D016001:Confidence Intervals; D003362:Cost-Benefit Analysis; D005602:France; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D007558:Italy; D018803:Models, Economic; D011878:Radiotherapy / Q000191:economics; D016019:Survival Analysis; D013557:Switzerland; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab